Predicting a Response to a Cell-Based Immune Modulating Cancer Therapy

Categories: “Cancer Therapeutics

Reference #: 2023-016

OTC Contact: Ruchika Nijhara, Ph.D., MBA, CLP (Directory Information | Send a Message)


Georgetown researchers have designed a novel and innovative that has the potential to serve as a prognostic indicator for CAR-T therapy efficacy in patients. The method uses primary tumor biopsies and CAR- T cells in the zebrafish xenograft model to predict which patients will respond to such therapy before the therapy.


While chimeric antigen receptor T (CAR-T) cells have emerged as a promising immune therapy for treating multiple types of cancer, over 50% of patients still do not respond to treatment and eventually relapse within six months. Clinicians currently have no way to test the efficacy of CAR-T therapy before prescribing it. Given that the treatment costs about $500,000 a patient and is limited by manufacturing capacity, having a reliable model that can provide prognostic information to clinicians is a game changer in human cancer treatments. CAR-T cell therapy has shown considerable promise for hematologic malignancies. Great efforts are being made to ensure CAR-T cells’ high effectiveness in patients with no other treatment option. Testing CAR-T strategies in mice is expensive, laborious, and slow.



Stage of Development

Studies are being conducted to develop the imaging modality (fluorescence) and the software image package to analyze fluorescence differences over time.

Patent Status

Provisional application filed.


Alexander Lekan

Eric Glasgow